Galapagos delivers validated oncology targets to Janssen
In January 2008, BioFocus entered into a fee-for-service target discovery collaboration with Janssen, under which BioFocus developed assays in cancer cells, and discovered and validated novel targets. In January 2010, BioFocus received a target acceptance payment from Janssen for identifying and validating drug targets. BioFocus has now confirmed the activity of a panel of targets across several key pathways in oncology, per contractually defined criteria. BioFocus may receive success-based payments should certain downstream criteria be reached by Janssen.
"We continue to see strong demand for our target discovery capabilities and this collaboration is an example of how we deliver novelty to pharmaceutical pipelines," said Onno van de Stolpe, Chief Executive Officer of Galapagos.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.